JP2018522555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522555A5 JP2018522555A5 JP2018502163A JP2018502163A JP2018522555A5 JP 2018522555 A5 JP2018522555 A5 JP 2018522555A5 JP 2018502163 A JP2018502163 A JP 2018502163A JP 2018502163 A JP2018502163 A JP 2018502163A JP 2018522555 A5 JP2018522555 A5 JP 2018522555A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- peptide
- seq
- disease
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 102
- 239000008194 pharmaceutical composition Substances 0.000 claims description 45
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 239000003623 enhancer Substances 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 102000004310 Ion Channels Human genes 0.000 claims description 3
- 208000028389 Nerve injury Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 3
- 238000000185 intracerebroventricular administration Methods 0.000 claims description 3
- 125000003473 lipid group Chemical group 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 230000008764 nerve damage Effects 0.000 claims description 3
- 239000012929 tonicity agent Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 230000008499 blood brain barrier function Effects 0.000 claims 6
- 210000001218 blood-brain barrier Anatomy 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 4
- 208000023589 ischemic disease Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 208000031225 myocardial ischemia Diseases 0.000 claims 4
- 208000020431 spinal cord injury Diseases 0.000 claims 4
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 33
- 230000000324 neuroprotective effect Effects 0.000 description 32
- 238000000034 method Methods 0.000 description 26
- 208000006011 Stroke Diseases 0.000 description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000007911 parenteral administration Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 5
- 238000007914 intraventricular administration Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000000816 peptidomimetic Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 239000002708 spider venom Substances 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015902845A AU2015902845A0 (en) | 2015-07-17 | ASIC1a modulators inspired by spider venom peptides | |
| AU2015902845 | 2015-07-17 | ||
| PCT/AU2016/050633 WO2017011863A1 (en) | 2015-07-17 | 2016-07-18 | Neuroprotective agents derived from spider venom peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522555A JP2018522555A (ja) | 2018-08-16 |
| JP2018522555A5 true JP2018522555A5 (https=) | 2019-08-22 |
| JP6818215B2 JP6818215B2 (ja) | 2021-01-20 |
Family
ID=57833496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502163A Active JP6818215B2 (ja) | 2015-07-17 | 2016-07-18 | クモ毒ペプチド由来の神経保護剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10485847B2 (https=) |
| EP (1) | EP3325503A4 (https=) |
| JP (1) | JP6818215B2 (https=) |
| AU (1) | AU2016295423B2 (https=) |
| WO (1) | WO2017011863A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10485847B2 (en) | 2015-07-17 | 2019-11-26 | The University Of Queensland | Neuroprotective agents derived from spider venom peptides |
| CA3057881A1 (en) | 2017-04-04 | 2018-10-11 | Baylor University | Targeted mosquitocidal toxins |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925664A (en) | 1986-10-20 | 1990-05-15 | University Of Utah | Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function |
| DE60112424T2 (de) * | 2000-05-10 | 2006-05-24 | Centre National De La Recherche Scientifique (Cnrs) | Protonen-abhängiges na+-kanal hemmendes polypeptid |
| WO2007030580A2 (en) * | 2005-09-09 | 2007-03-15 | Oregon Health & Science University | Neuroprotectants |
| BRPI0605484A8 (pt) * | 2006-11-21 | 2017-03-07 | Fund Amparo Pesquisa Estado Minas Gerais Fapemig | Toxina ph(alfa)1b, cdna do gene da toxina ph(alfa)1b, composições farmacêuticas contendo a toxina ph(alfa)1b, processo para sua obtenção, processo para obtenção do cdna, e produto |
| NZ727213A (en) * | 2012-03-09 | 2020-03-27 | Vestaron Corp | Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides |
| US10485847B2 (en) | 2015-07-17 | 2019-11-26 | The University Of Queensland | Neuroprotective agents derived from spider venom peptides |
-
2016
- 2016-07-18 US US15/745,432 patent/US10485847B2/en active Active
- 2016-07-18 WO PCT/AU2016/050633 patent/WO2017011863A1/en not_active Ceased
- 2016-07-18 EP EP16826924.9A patent/EP3325503A4/en active Pending
- 2016-07-18 AU AU2016295423A patent/AU2016295423B2/en active Active
- 2016-07-18 JP JP2018502163A patent/JP6818215B2/ja active Active
-
2019
- 2019-10-11 US US16/599,788 patent/US10881712B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513720A5 (https=) | ||
| JP2018509935A5 (https=) | ||
| US9809823B2 (en) | DNA aptamers for promoting remyelination | |
| US11110152B2 (en) | Compositions and methods for treating and preventing lung disease | |
| JP2024522385A5 (https=) | ||
| JP2007528890A (ja) | 呼吸器疾患の抗ウイルス療法のためのインターフェロン−β | |
| JP5981141B2 (ja) | 多臓器不全症候群（ｍｏｄｓ）の予防および／または処置のためのインターロイキン−２２の使用 | |
| KR20230155941A (ko) | 신규한 e3 리가아제 리간드 및 이의 용도 | |
| JP2018522555A5 (https=) | ||
| F Nahhas et al. | Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics | |
| US10548946B2 (en) | Therapeutic compositions for neutralizing type I interferons, and methods of use | |
| Chiu et al. | Peptide pharmacological approaches to treating traumatic brain injury: a case for arginine-rich peptides | |
| JP5926200B2 (ja) | インフルエンザ様疾患の治療 | |
| CN103501794A (zh) | 脑靶向性功能性核酸及其利用 | |
| JP2020530453A5 (https=) | ||
| JP2008531463A5 (https=) | ||
| US10160791B2 (en) | Protamine in treatment of neuronal injuries | |
| JP7783830B2 (ja) | 肺疾患を治療及び予防するための組成物及び方法 | |
| JP2018522555A (ja) | クモ毒ペプチド由来の神経保護剤 | |
| US11548919B1 (en) | SARS-CoV-2 polypeptide inhibitors directed against the Env TM domain and methods of treatment using said inhibitors | |
| JP6183879B2 (ja) | 新規ペプチドおよびその医薬用途 | |
| JP2013545459A5 (https=) | ||
| WO2007118431A1 (zh) | Trap 蛋白自身作为活性成分在制备治疗金黄色葡萄球菌感染的药物中的应用 | |
| JP2024518565A (ja) | 組換え重複ペプチド及びネイティブタンパク質を含むワクチン製剤 | |
| US20210379141A1 (en) | Compositions and methods for treating and preventing lung disease |